NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Pediatric Growth Hormone Deficiency (PGHD): Early Recognition, Diagnosis, and Treatment Options
TL;DR
Parents can gain an advantage by advocating for specialists and weekly treatments, ensuring optimal growth outcomes for children with PGHD.
PGHD diagnosis involves blood tests, bone age X-rays, growth hormone stimulation tests, and MRIs, with treatment using somatropin injections, including weekly options.
Early PGHD detection and treatment improve children's health and growth, fostering better family well-being and future opportunities through persistent medical advocacy.
A mother's persistence led to diagnosing her son's rare PGHD, highlighting the shift from daily to weekly growth hormone treatments for easier management.
Found this article helpful?
Share it with your network and spread the knowledge!
PGHD is a rare condition where the pituitary gland doesn't produce enough growth hormone, affecting an estimated 1 in 4,000-10,000 children.
Parents might notice their child being significantly shorter than peers, slower growth rate over time, delayed puberty, reduced muscle strength or lower energy levels, slower bone development, and delayed physical milestones.
After a friend's child was diagnosed with PGHD, Alex's mother sought a pediatric endocrinologist who conducted bloodwork, a bone age X-ray, a growth hormone stimulation test, and a brain MRI to confirm the diagnosis.
The standard treatment has been daily injections of somatropin, but since 2015, long-acting growth hormone (LAGH) offering once-weekly dosing has been recognized as an alternative.
Their insurance required trying daily medication for three months before approving the weekly option, during which Alex often missed doses due to the inconvenience.
Early detection can help minimize the impact on overall health and support optimal growth in children with PGHD.
The weekly option created minimal disruptions to their daily routine, and Alex hasn't missed a single dose since switching, making a positive impact.
The article suggests seeking a specialist like a pediatric endocrinologist for further evaluation, as demonstrated by Alex's mother who persisted despite initial dismissals.
Curated from Noticias Newswire
